Düsseldorf, Germany Wednesday, February 5, 2025, 18:00 Hrs [IST] ...
In 2004, a research group at Peking University First Hospital discovered a mutation in the gene coding for a sodium-channel ...
The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx ...
Allosteric GABAA-receptor modulator AP-325 showed rapid onset as well as long-lasting pain reduction in patients with chronic neuropathic pain in Phase 2a study Data confirm previously reported ...
Algiax Pharmaceuticals, a clinical-stage biotech company focused on developing innovative treatments for chronic neuropathic pain, today announced compelling topline data from its Phase 2a clinical ...
Woman's World on MSN5d
FDA Approves New Non-Opioid Painkiller for Acute Pain-What to Know!A massive stride has been made in the pain medication industry. The U.S. Food and Drug Administration (FDA) announced Thursday its approval of a non-opioid treatment for moderate to severe acute pain ...
Zacks.com on MSN6d
VRTX Gets FDA Nod for Non-Opioid Pain Drug Journavx, Shares UpVertex Pharmaceuticals Incorporated VRTX announced that the FDA has approved its oral, non-opioid, highly selective NaV1.8 pain signal inhibitor, suzetrigine, for the treatment of adults with moderate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback